[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EA201592049A1 - Антитело с "запирающими" свойствами для инактивации лекарства белкового происхождения - Google Patents

Антитело с "запирающими" свойствами для инактивации лекарства белкового происхождения

Info

Publication number
EA201592049A1
EA201592049A1 EA201592049A EA201592049A EA201592049A1 EA 201592049 A1 EA201592049 A1 EA 201592049A1 EA 201592049 A EA201592049 A EA 201592049A EA 201592049 A EA201592049 A EA 201592049A EA 201592049 A1 EA201592049 A1 EA 201592049A1
Authority
EA
Eurasian Patent Office
Prior art keywords
antibody
hinge region
benchmarking
inactivation
origin
Prior art date
Application number
EA201592049A
Other languages
English (en)
Other versions
EA035322B1 (ru
Inventor
Тянь-Лу Чэн
Чи-Хун Чуан
Хсю-Фень Ко
Юнь-Чи Люй
Original Assignee
ДиЭсБи-ЮЭсЭй ЛЛК
Гаосюн Медикл Юниверсити
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ДиЭсБи-ЮЭсЭй ЛЛК, Гаосюн Медикл Юниверсити filed Critical ДиЭсБи-ЮЭсЭй ЛЛК
Publication of EA201592049A1 publication Critical patent/EA201592049A1/ru
Publication of EA035322B1 publication Critical patent/EA035322B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

Данное изобретение предусматривает антитело с шарнирной областью, способное селективно активироваться в клетке-мишени или в ткани-мишени для лечения заболевания. Антитело с шарнирной областью включает функциональное антитело, два ингибиторных домена и четыре отщепляемых линкера. Функциональное антитело в активированном состоянии способно к лечению указанного заболевания и содержит две лёгкие цепи и две тяжёлые цепи. Каждый ингибиторный домен включает шарнирный домен иммуноглобулина и состоит из двух пептидных плечей. Каждый отщепляемый линкер включает пептидный субстрат, расщепляемый ферментом, который специфически или с высокой степенью экспрессирован в клетке-мишени или в ткани-мишени и соединяет одно из пептидных плечей ингибиторных доменов с N-концом одной из лёгких цепей и тяжёлых цепей функционального антитела. Предусмотрены также способы получения и применения антитела с шарнирной областью по изобретению.
EA201592049A 2013-05-28 2014-05-28 Антитело с "запирающими" свойствами для инактивации лекарства белкового происхождения EA035322B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361827763P 2013-05-28 2013-05-28
PCT/US2014/039821 WO2014193973A2 (en) 2013-05-28 2014-05-28 Antibody locker for the inactivation of protein drug

Publications (2)

Publication Number Publication Date
EA201592049A1 true EA201592049A1 (ru) 2016-04-29
EA035322B1 EA035322B1 (ru) 2020-05-28

Family

ID=51989521

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201592049A EA035322B1 (ru) 2013-05-28 2014-05-28 Антитело с "запирающими" свойствами для инактивации лекарства белкового происхождения

Country Status (15)

Country Link
US (1) US10633453B2 (ru)
EP (1) EP3003370B1 (ru)
JP (1) JP6545666B2 (ru)
KR (1) KR102182485B1 (ru)
CN (1) CN105377297B (ru)
AU (1) AU2014274215B2 (ru)
CA (1) CA2913051C (ru)
EA (1) EA035322B1 (ru)
HK (1) HK1221426A1 (ru)
IL (1) IL242772B (ru)
MX (1) MX2015016329A (ru)
SG (2) SG10201710727UA (ru)
TW (1) TWI582111B (ru)
WO (1) WO2014193973A2 (ru)
ZA (1) ZA201508673B (ru)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10633453B2 (en) 2013-05-28 2020-04-28 Kaohsiung Medical University Antibody locker for the inactivation of protein drug
CA2925106C (en) 2013-09-25 2023-11-14 Cytomx Therapeutics, Inc. Matrix metalloproteinase substrates and other cleavable moieties and methods of use thereof
TWI701261B (zh) 2013-12-17 2020-08-11 美商建南德克公司 抗cd3抗體及使用方法
ES2932777T3 (es) 2014-01-31 2023-01-25 Cytomx Therapeutics Inc Sustratos de matriptasa y activador del plasminógeno-u y otros motivos escindibles y métodos de uso de los mismos
SG11201701627PA (en) 2014-09-12 2017-03-30 Genentech Inc Anti-cll-1 antibodies and immunoconjugates
MA41374A (fr) * 2015-01-20 2017-11-28 Cytomx Therapeutics Inc Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci
AU2016229408A1 (en) 2015-02-25 2017-09-14 Memorial Sloan-Kettering Cancer Center Use of inactivated nonreplicating modified vaccinia virus ankara (mva) as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors
EP3283088A4 (en) 2015-04-17 2018-10-24 Memorial Sloan-Kettering Cancer Center Use of mva or mvadeltae3l as immunotherapeutic agents against solid tumors
EP3288981A1 (en) * 2015-05-01 2018-03-07 Genentech, Inc. Masked anti-cd3 antibodies and methods of use
ES2889906T3 (es) 2015-05-21 2022-01-14 Harpoon Therapeutics Inc Proteínas de unión triespecíficas y usos médicos
JP6996983B2 (ja) 2015-06-16 2022-02-21 ジェネンテック， インコーポレイテッド 抗ｃｌｌ－１抗体及び使用方法
CN108135968A (zh) 2015-08-28 2018-06-08 阿穆尼克斯运营公司 嵌合多肽组装体及其制备和使用方法
EP4310503A3 (en) * 2015-12-30 2024-03-20 Momenta Pharmaceuticals, Inc. Methods related to biologics
US10736962B2 (en) 2016-02-25 2020-08-11 Memorial Sloan Kettering Cancer Center Recombinant MVA or MVADELE3L expressing human FLT3L and use thereof as immuno-therapeutic agents against solid tumors
AU2017222686B2 (en) 2016-02-25 2021-12-23 Memorial Sloan Kettering Cancer Center Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human Flt3L or GM-CSF for cancer immunotherapy
WO2017165306A1 (en) * 2016-03-20 2017-09-28 Middle Tennessee State University ASSAY FOR HIGH-THROUGHPUT lDENTIFICATION OF THERAPEUTIC COMPOUNDS
US11542332B2 (en) 2016-03-26 2023-01-03 Bioatla, Inc. Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
CA3024448A1 (en) * 2016-05-18 2017-11-23 Voyager Therapeutics, Inc. Modulatory polynucleotides
CN107446016A (zh) * 2016-05-30 2017-12-08 上海交通大学 一种硬脂酸修饰的细胞穿膜肽及其制备与应用
TW201809013A (zh) 2016-06-06 2018-03-16 艾斯克立必恩股份有限公司 用於藥物遞送之抗體融合蛋白
CA3042679A1 (en) * 2016-11-03 2018-05-11 Bristol-Myers Squibb Company Activatable anti-ctla-4 antibodies and uses thereof
KR20190074300A (ko) 2016-11-15 2019-06-27 제넨테크, 인크. 항-cd20/항-cd3 이중특이적 항체에 의한 치료를 위한 투약
JP2020500900A (ja) 2016-12-09 2020-01-16 シアトル ジェネティクス インコーポレーテッド コイルドコイルでマスキングされた二価抗体
CA3048467A1 (en) * 2016-12-29 2018-07-05 Development Center For Biotechnology Klk6-mediated cns-specific antibody prodrug activation
EP3621646A4 (en) 2017-05-12 2021-06-02 Memorial Sloan Kettering Cancer Center VACCINIA VIRUS MUTANTS FOR CANCER IMMUNOTHERAPY
EP3625253A4 (en) 2017-05-16 2021-03-24 Scalmibio, Inc. ACTIVABLE ANTIBODIES AND THEIR METHODS OF USE
KR20220111743A (ko) 2017-10-13 2022-08-09 하푼 테라퓨틱스, 인크. B 세포 성숙화 항원 결합 단백질
TWI831759B (zh) 2017-12-01 2024-02-11 美商思進公司 Cd47抗體及其用於治療癌症之用途
JP7475275B2 (ja) 2018-02-08 2024-04-26 ジェネンテック， インコーポレイテッド 二重特異性抗原結合分子及びその使用方法
KR102245552B1 (ko) * 2018-02-28 2021-04-29 부산대학교 산학협력단 나노약물 복합체, 이의 제조방법 및 이의 용도
JP7438122B2 (ja) * 2018-03-13 2024-02-26 メモリアル スローン－ケタリング キャンサー センター 免疫チェックポイント遮断を発現する癌免疫療法のための腫瘍溶解性ワクシニアウイルス
EP3856771A4 (en) 2018-09-25 2022-06-29 Harpoon Therapeutics, Inc. Dll3 binding proteins and methods of use
BR112021010433A2 (pt) 2018-12-06 2021-08-24 Cytomx Therapeutics, Inc. Substratos cliváveis de metaloprotease de matriz e de serina ou cisteína protease e métodos de uso destes
US20220306727A1 (en) 2019-06-05 2022-09-29 Seagen Inc. Methods of Purifying Masked Antibodies
WO2020247572A1 (en) 2019-06-05 2020-12-10 Seattle Genetics, Inc. Masked antibody formulations
WO2023288236A1 (en) 2021-07-14 2023-01-19 Seagen Inc. Antibody masking domains
EP4405387A1 (en) 2021-09-24 2024-07-31 Seagen Inc. Improved antibody masking domains
WO2023064945A2 (en) * 2021-10-15 2023-04-20 Harpoon Therapeutics, Inc. Conditional activation of immunoglobulin molecules
WO2023222580A1 (en) 2022-05-16 2023-11-23 Byondis B.V. Novel masked antibodies

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
GB9322156D0 (en) 1993-10-27 1993-12-15 Univ Newcastel Upon Tyne Activation of molecules
JP4212111B2 (ja) 1995-05-03 2009-01-21 バイオエンハンスメンツ リミテッド 結合能力が光開裂性分子により可逆的に阻害される二重特異性抗体
US20040014652A1 (en) 2000-06-01 2004-01-22 Andre Trouet Tumor activated prodrug compounds and methods of making and using the same
US7238505B2 (en) 2000-10-04 2007-07-03 Ahram Biosystems Inc. Immobilized DNA polymerase
BR0213565A (pt) * 2001-11-12 2004-10-26 Merck Patent Gmbh Anticorpo de anti-tnf alfa modificado
WO2003068934A2 (en) 2002-02-14 2003-08-21 Rutter William J Chimeric molecules for cleavage in a treated host
US20040109855A1 (en) 2002-07-23 2004-06-10 Herman Waldmann Therapeutic antibodies with reduced side effect
WO2004111608A2 (en) 2003-06-09 2004-12-23 Mcintyre John A Method of altering the binding specificity of plasma proteins by oxidation-reduction reactions
GB0404187D0 (en) 2004-02-25 2004-03-31 Biotransformations Ltd Binding agents
MX2007004374A (es) * 2004-10-12 2008-01-29 Amprotein Corp Proteina quimerica.
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
GB0605702D0 (en) 2006-03-21 2006-05-03 Biotransformations Ltd Materials and methods for immune cell stimulation
AT503902B1 (de) * 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw Verfahren zur manipulation von immunglobulinen
US9624309B2 (en) 2007-08-15 2017-04-18 Bayer Intellectual Property Gmbh Monospecific and multispecific antibodies and method of use
GB0716160D0 (en) 2007-08-17 2007-09-26 Biotransformations Ltd Materials and methods for treating cancers which express folate receptors
CA3128656A1 (en) * 2007-08-22 2009-02-26 The Regents Of The University Of California Activatable binding polypeptides and methods of identification and use thereof
JP5448397B2 (ja) * 2007-09-07 2014-03-19 キヤノン株式会社 基質プローブ、多重核磁気共鳴法による酵素活性の検出方法および酵素活性のイメージング方法
WO2010077643A1 (en) 2008-12-08 2010-07-08 Tegopharm Corporation Masking ligands for reversible inhibition of multivalent compounds
CA2749339A1 (en) 2009-01-12 2010-07-15 Cytomx Therapeutics, Llc Modified antibody compositions, methods of making and using thereof
CA2753294A1 (en) * 2009-02-23 2010-08-26 Cytomx Therapeutics, Inc. Proproteins and methods of use thereof
RU2015153109A (ru) 2009-09-16 2019-01-15 Дженентек, Инк. Содержащие суперспираль и/или привязку белковые комплексы и их применения
CA2796633C (en) * 2010-04-23 2020-10-27 Genentech, Inc. Production of heteromultimeric proteins
JP5758004B2 (ja) 2010-08-24 2015-08-05 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ジスルフィドによって安定化されたＦｖ断片を含む二重特異性抗体
EP2609112B1 (en) 2010-08-24 2017-11-22 Roche Glycart AG Activatable bispecific antibodies
EP2624868B1 (en) 2010-10-08 2018-09-26 City of Hope A monoclonal antibody framework binding interface for meditopes, meditope delivery systems and methods for their use
CN103649125A (zh) * 2011-06-22 2014-03-19 霍夫曼-拉罗奇有限公司 利用包含mhc i类的复合物通过循环中的病毒特异性细胞毒性t细胞清除靶细胞
GB201203442D0 (en) 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
KR20150030639A (ko) 2012-03-30 2015-03-20 바이엘 헬스케어 엘엘씨 프로테아제로 조절된 항체
CN110078827A (zh) 2012-04-27 2019-08-02 西托姆克斯治疗公司 结合表皮生长因子受体的可活化的抗体其使用方法
WO2013192546A1 (en) 2012-06-22 2013-12-27 Cytomx Therapeutics, Inc. Activatable antibodies having non-binding steric moieties and mehtods of using the same
CN104661677A (zh) 2012-06-22 2015-05-27 西托姆克斯治疗公司 抗Jagged 1/Jagged 2交叉反应抗体、可活化的抗Jagged抗体及其使用方法
WO2014052462A2 (en) 2012-09-25 2014-04-03 Cytomx Therapeutics, Inc. Activatable antibodies that bind interleukin-6 receptor and methods of use thereof
JP2016514687A (ja) * 2013-03-15 2016-05-23 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ 組織因子経路インヒビターに対するプロドラッグ抗体
US10633453B2 (en) 2013-05-28 2020-04-28 Kaohsiung Medical University Antibody locker for the inactivation of protein drug
DK3024851T3 (en) 2013-07-25 2018-08-06 Cytomx Therapeutics Inc MULTI-SPECIFIC ANTIBODIES, MULTI-SPECIFICALLY ACTIVABLE ANTIBODIES, AND METHODS FOR USING IT
CA2925106C (en) 2013-09-25 2023-11-14 Cytomx Therapeutics, Inc. Matrix metalloproteinase substrates and other cleavable moieties and methods of use thereof
US9540440B2 (en) 2013-10-30 2017-01-10 Cytomx Therapeutics, Inc. Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
DE102014201538A1 (de) 2014-01-29 2015-07-30 Robert Bosch Gmbh Verfahren zum Ansteuern eines Parkplatz-Managementsystems für mindestens einen Parkplatz und Parkplatz-Managementsystem für mindestens einen Parkplatz

Also Published As

Publication number Publication date
SG11201509595PA (en) 2015-12-30
WO2014193973A3 (en) 2015-02-19
CA2913051C (en) 2023-09-05
CN105377297B (zh) 2019-09-17
WO2014193973A2 (en) 2014-12-04
TWI582111B (zh) 2017-05-11
IL242772B (en) 2020-04-30
HK1221426A1 (zh) 2017-06-02
SG10201710727UA (en) 2018-02-27
EP3003370A4 (en) 2017-01-25
TW201520230A (zh) 2015-06-01
MX2015016329A (es) 2016-07-20
EP3003370A2 (en) 2016-04-13
JP2016520614A (ja) 2016-07-14
US10633453B2 (en) 2020-04-28
EP3003370B1 (en) 2020-01-22
CN105377297A (zh) 2016-03-02
EA035322B1 (ru) 2020-05-28
KR102182485B1 (ko) 2020-11-25
AU2014274215B2 (en) 2019-02-28
KR20160032041A (ko) 2016-03-23
US20160185875A1 (en) 2016-06-30
AU2014274215A1 (en) 2015-12-03
CA2913051A1 (en) 2014-12-04
JP6545666B2 (ja) 2019-07-17
ZA201508673B (en) 2017-05-31

Similar Documents

Publication Publication Date Title
EA201592049A1 (ru) Антитело с "запирающими" свойствами для инактивации лекарства белкового происхождения
CY1123030T1 (el) Υλικο και μεθοδοι για θεραπεια ή αποτροπη σχετικων me her-3 ασθενειων
BR112013007314A2 (pt) anticorpos anti-cd48 e seus usos
PE20121616A1 (es) Anticuerpos anti-her3
BR112016011025A2 (pt) polipeptídeos anticorpo e seus usos
CY1124153T1 (el) Αντισωματα και πολυπεπτιδια που κατευθυνονται εναντι cd127
EA201890315A1 (ru) Молекулы антител, связывающие cd22
PE20181805A1 (es) Composiciones y anticuerpos anti-tim-3
WO2018091740A3 (en) Novel anti_cd137 antibodies and uses thereof
BR112015013127A2 (pt) imunoterapia com agentes de ligação
EA200870185A1 (ru) Комбинации ингибиторов ang2 и vegf
DOP2017000031A (es) Anticuerpo monoclonal anti-ctla4 o su fragmento de unión a antígeno, una composición farmacéutica y uso
UY33204A (es) Metodos y composiciones usando polipeptidos de fusion de fgf23
PH12016502590B1 (en) Covalently bonded diabodies having immunoreactivity with pd-1 and lag-3, and methods of use thereof
PE20161032A1 (es) Anticuerpos anti-tau(ps422) humanizados y metodos de utilizacion
AR091069A1 (es) Proteinas de union a antigeno dirigidas contra el receptor st2
GT201200318A (es) Anticuerpos hacia gdf8 humano
EA201070636A1 (ru) Ингибирование рецептора белка, стимулирующего макрофаги (ron), и способы его лечения
UA109633C2 (uk) Антитіло людини проти тканинного фактора
CL2011000117A1 (es) Anticuerpo de dominio (dab) que se unen a cd28 y previene la union de dicha proteina a cd80 y/o cd86; uso del anticuerpo para tratar una enfermedad inmune; y composicion farmaceutica que lo comprende.
NO20081354L (no) Dobbelt variabelt domeneimmunoglobin samt fremgangsmater derav
BR112012013038A2 (pt) mutantes fc de anticorpo com funções efetoras ablacionadas
EA201390472A1 (ru) Новые молекулы, связывающиеся с egfr, и их иммуноконъюгаты
BR112012019098A2 (pt) composição farmacêutica, combinação farmacêutica e método para o tratamento e/ou prevenção de um câncer e anticorpo
EA201890320A1 (ru) Молекулы антител, которые связывают cd79

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM